The Australian Prostate Cancer BioResource (APCB) provides a unique quality assured facility for the collection, storage and access to biospecimens and annotated clinical data to support research into the treatment and improved clinical management of men with prostate cancer. The APCB manages four federated nodes located in Brisbane, Sydney, Melbourne and Adelaide.
- To provide an internationally “best practice” Biobank underpinning translational research into prostate cancer.
- To provide long term clinical follow up data related to prostate cancer treatment that will allow for meaningful outcome based research (currently <10 years) .
- To provide standardised high quality derivatives of Biobank biological samples – DNA, RNA, and TMAs upon request in some states.
- To facilitate collections in developing areas of research – circulating tumour cells (CTCs), primary cells, tissue explants and xenograft models.
- To collaborate with and participate in consortia and major programs of research activity including clinical trials.
- To establish a community of practice focussed on the biobanking of prostate cancer biological samples.
What we do
The APCB provides a significant number of unique services which include:
- Fresh tissue (cancer/”benign” cores) from radical prostatectomies;
- Paraffin embedded tissue sections,
- Buffy coat cells, serum, plasma
History of APCB
This APCB was an initiative of the Australian Prostate Cancer Collaboration; a group of clinicians, scientists and other health professionals dedicated to improving prostate cancer management. The bioresource was established by this group to ensure high quality annotated prostate biological samples were available to all Australian prostate cancer researchers. The APCB is indebted to our foundation sponsors including the PCFA, the Commonwealth Bank of Australia and Andrology Australia for having the foresight to sponsor such an important resource. And the Australian Government or their decade long sponsorship.
Established with the support
The APCB was jointly established by two enabling grants from the National Health and Medical Research Council (NHMRC) and Prostate Cancer Foundation of Australia (PCFA).